Latest Articlesddd
As we wrote in Prohost Letter #409, a transformation in this year’s American Society of Clinical Oncology …
Alnylam Pharmaceutical (ALNY) calls RNAi (RNA interference) a revolution in biology. The FDA’s just granted the …
It is obvious that the CAR-T approach to cancer treatment is here to stay and to …
Array Biopharma (ARRY) and Bristol-Myers Squibb (BMY) announced a clinical research collaboration to investigate the safety, …
Prohost Letter #409 ASCO The American Society of Clinical Oncology (ASCO) meeting is around the corner. …
GlycoMimetics (GLYN) is a development-stage biotechnology company focused on cancer and sickle cell disease. The firm’s most …
Amgen’s (AMGN) and UCB's drug Evenity (romosozumab), which, in long and large 24 months of clinical …
As a matter of fact, we consider Incyte’s (INCY) drug epacadostat’s good results extremely important. The reason? Two …
PTC THERAPEUTICS Why Buying Emflaza? Buying Emflaza, a steroid approved by the FDA for Duchenne muscular …
AKEBIA THERAPEUTICS? Akebia Therapeutics (AKBA) whose stock trades on the NASDAQ is outperforming. The firm’s drug …
GENE EDITING Sangamo Biosciences: Is it a Comeback? Genome editing allows the creation of therapeutics that …
AT A GLANCE IMPORTANT NEWS A New FDA Commissioner The U.S. Senate Voted in Favor of …
Positive results were announced from Array’s (ARRY) Part 2 of the Phase 3 COLUMBUS study evaluating …
Indeed, Saving One Life is Important. Yet, Important Too is Saving Many Lives The Risk Vs. …
EPIZYME Many oncologists, we believe, must be impatient to learn about the outcome of a first-in-class …
Novartis signed two different separate licensing agreements with two development-stage firms, Bluebird (BLUE) and Celyad (CYAD). …
MERCK Merck (MRK) has beaten analysts’ expectations generating $9.4 billion for revenues in the first quarter …
MIGRAINE Migraine might have a new potent preventive treatment on the market in the near future. …
ImmunoGen is one of two firms Prohost selected for investment on February 2011 based on the …
Prohost Letter #408 AT A GLANCE - Continued from the Previous Prohost Letter #408 In the …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
